Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection

Tilling, Richarda; Kinloch, Sabinea; Goh, Li-Eanb; Cooper, Davidc; Perrin, Lucd; Lampe, Fionae; Zaunders, Johnc; Hoen, Brunof; Tsoukas, Chrisg; Andersson, Janh; Janossy, Georgea; on behalf of the Quest Study Group


Objectives: To monitor changes in the numbers of CD8 lymphocytes expressing the activated CD38++ phenotype in peripheral blood samples from patients with primary HIV infection (PHI) treated with highly active antiretroviral therapy (HAART).

Methods: Zidovudine, lamivudine, abacavir and amprenavir were initiated during PHI as part of the Quest study. Absolute numbers of CD8+/CD38++ T cells were determined using three-colour flow cytometry, and plasma viral load (VL) was measured using the Roche Amplicor method.

Results: The median, pre-therapy CD8+/CD38++ T cell count was 461/mm3 (interquartile range 216, 974) in 131 patients compared with normal control values of less than 20 cells/mm3. Levels fell markedly in parallel with VL within the first 2 weeks of HAART initiation, to a median of 47 cells/mm3at 28 weeks (median 436 cell decline;P < 0.001). At that time, 80% of patients had a VL less than 50 copies/ml, and 16.3% of all patients had less than 20 CD8+/CD38++ T cells/mm3. A continued decrease in CD8+/CD38++ T cell count occurred in 67.2% of patients whose VL was maintained below 50 copies/ml (median change from first to last value −18 cells/mm3;P < 0.001).

Conclusion: After the initiation of HAART in PHI, CD8+/CD38++ lymphocytes declined rapidly in parallel with VL, and allowed for a normalization of CD8+/CD38++ T cell numbers in a subset of patients at week 28. Cell numbers continued to decline in patients who maintained VL below 50 copies/ml, indicating that the CD8+/CD38++ T cell count may represent a marker of residual viral replication when VL falls below detectable levels after HAART intervention.

Author Information

From the aDepartment of Immunology and Molecular Pathology, Royal Free and University College Medical School, Royal Free Campus, London NW3 2QG, UK; bDepartment of HIV and Opportunistic Infections, GlaxoSmithKline Research and Development, Greenford Road, Middx UB6 0HE, UK; cNational Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Sydney, NSW 2010, Australia; dHôpital Cantonal, Département de Médecine interne, Division des Maladies Infectieuses, Laboratoire Central de Virologie, Rue Micheli-du-Crest 24, 1211 Genève 14, Switzerland; eRoyal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK; fUniversite de Franche-Comte, Department of Infectious Diseases, University Medical Centre, 25030 Besancon, France; gMontreal General Hospital, Immune Deficiency Treatment Centre, Montreal, Quebec H3G 1A4, Canada; and hKarolinska Institutet, Division of Infectious Diseases, Huddinge University Hospital, Huddinge, Sweden.

Correspondence and requests for reprints to: Dr L. Goh, Department of HIV and Opportunistic Infections, GlaxoSmithKline Research and Development, Greenford Road, Middlesex UB6 0HE, UK. Tel: +44 020 8966 2980; fax: +44 020 8869 3310; e-mail:

Received: 19 January 2001;

revised: 16 August 2001; accepted: 9 October 2001.

Article Outline
Back to Top | Article Outline


Infection by HIV in the absence of antiretroviral therapy is characterized by chronic T cell activation [1]. Among the various markers of T cell activation, the number of CD8 cells with the CD38+ phenotype is known to be raised in both acute and chronic infection [2–11]. There is some debate over the function of these cells, which could represent HIV-specific or cytokine-activated cells [8,9,12]. Individuals with high levels of CD8+/CD38++ cells during chronic HIV infection tend to experience a faster CD4 cell decline [13], and develop clinical disease more rapidly than those with lower levels [11,14–19]. This association persists even after adjusting for baseline CD4 cell count and viral load (VL) [14,20], suggesting that additional factors involved in HIV pathogenesis contribute to high levels of CD38 cells. It has also been shown that the initiation of antiretroviral therapy is associated with a reduction in the percentage and absolute number of circulating CD8+/CD38++ cells in both acute and chronic infection [5,6,21–27].

Recent methodological improvements in the techniques used to quantitate CD38 cell surface molecule expression has allowed us to focus on a population of active CD8 T cells that express high levels of this molecule [28–30]. Instead of a bulk assay that measures the mean expression of CD38 molecules among the heterogeneous cohorts of CD8 cells [16,20,28], the utilization of a quantitative gating strategy permits the determination of the absolute numbers of CD8+/CD38++ T cells in whole blood [29]. As CD8 T cells expressing the CD38++ phenotype are rare in normal HIV-negative adults, the test for CD8+/CD38++ T cells can be regarded as a particularly sensitive flow cytometric assay for monitoring levels of immune activation in patients receiving a potent four-drug antiretroviral treatment regimen at the time of primary HIV infection (PHI). The objectives of the present investigation were to assess CD8+/CD38++ T cell levels before starting therapy, to describe their dynamics after the initiation of therapy, with attention to whether the levels of CD8+/CD38++ T cells return to those observed in uninfected individuals, to evaluate the associations between VL and CD8+/CD38++ T cells during therapy, and to assess changes in the levels of CD8+/CD38++ T cell levels in patients with VL below 50 copies/ml.

Back to Top | Article Outline

Materials and methods

Patients were participants in the Quest (GW PROB 3005) Study to evaluate the virological and immunological effects of early treatment intervention with potent quadruple antiretroviral therapy [combivir (zidovudine 300 mg plus lamivudine 150 mg), abacavir 300 mg and amprenavir 1200 mg twice a day] in PHI. The study also includes an added randomized vaccination strategy after at least 72 weeks of highly active antiretroviral therapy (HAART) [31]. Eligible patients had confirmed HIV infection defined by their detectable VL measured by HIV-RNA polymerase chain reaction and either a negative or an evolving antibody response. These were defined as antibody negative measured with the third-generation enzyme-linked immunosorbent assay (ELISA), or if having a positive ELISA, those who had no more than three bands on the HIV Western blot. Patients were enrolled into the study during the period February 1998 to October 1999 from clinical centres in Europe (France, Switzerland, UK, Italy, Sweden, Belgium, Germany, Denmark), Australia and Canada. Baseline (pre-therapy) blood samples were collected for the measurement of VL, T lymphocyte subsets and CD8+/CD38++ T cell counts. Further measurements were made on samples collected at weeks 2, 4, 12, 20, 28, 36, 48 and 96 of treatment.

Back to Top | Article Outline
Viral load measurement

Plasma VL was determined by HIV RNA, either using the current Roche Amplicor assay (Version 1.5; Roche Molecular Systems Inc., Alameida, CA, USA) with a lower limit of detection of 400 copies/ml or the Ultrasensitive method (Version 1.5; Roche Molecular Systems Inc., Alameida, CA, USA) with a lower limit of detection of 50 copies/ml. Assays were performed in one of two central laboratories: Covance GE, Switzerland or Sydpath, Sydney, Australia.

Back to Top | Article Outline
T cell subset measurements

Peripheral blood T cell subset measurements were routinely performed at two co-ordinated trial centres (Royal Free Hospital, London, UK and Sydpath, Sydney, Australia). Absolute CD4 and CD8 T cell counts were determined on 100 μl ethylenediamine tetraacetic acid blood, using a three-colour direct immunofluorescence method, involving a ‘lyse-no-wash’ technique [32]. In one sample tube, CD3+ T cells were autogated and analysed for CD4 and CD8 cell expression using CD4/CD8/CD3 cell triple staining. In the second tube, lymphocyte counts were obtained as the sum of CD3+ T cells, CD19+ B cells and CD16+ natural killer cells using CD16/CD19/CD3 cell triple staining. In a third tube, a titrated CD45RA/CD38/CD8 cell triple antibody cocktail was used. Here, CD8++T lymphocytes and lymphoblasts were gated in a CD8 cell/side scatter histogram and analysed for CD38 and CD45RA cell expression in a two-parameter histogram. Absolute counts were measured directly using a volumetric flow cytometer (Ortho Cytoron Absolute; Ortho Diagnostics, Amersham, UK) or by fluorescence-activated cell sorting (FACS; Becton Dickinson, Mountain View, CA, USA) [33]. The reagents used in the first two tubes were supplied by Ortho Diagnostics. For the third tube, a CD8 cell antibody conjugated to Tricolor was supplied by TCS Biological, Buckingham, UK, and both CD38 cells conjugated to phycoerythrin and CD45RA cells conjugated to fluorescein-isothiocyanate were supplied by Becton Dickinson, (Becton Dickinson, Oxford, UK). Percentages and absolute counts of lymphocyte subpopulations were determined using the Immunocount II software (Ortho Diagnostics). The median CD4 cell count in healthy HIV-negative individuals was 784 cells/mm3 (interquartile ranges; IQR 629, 1200) and the CD8 cell count was 307 cells/mm3 (IQR 225, 479).

Back to Top | Article Outline
Absolute CD8+/CD38++ cell measurement

The CD38++ cell numbers were counted on the Ortho Cytoron Absolute in London and on FACS in Sydney; both laboratories using a similar semi-quantitative gating strategy (Fig. 1). The flow cytometry gates were standardized in both centres on normal adult and fetal cord blood samples. In healthy adults, CD38 cell expression on CD8+ T cells of the ‘memory’ CD 45RO+ cell phenotype is low (CD38−, < 1500 CD38 molecules/cell) whereas 20–40% of CD8+ T cells of the CD45RA+ cell phenotype as well as granulocytes/neutrophils have an intermediate CD38 cell expression (CD38+; 1000–5000 CD38 molecules/cell). Monocytes (but virtually no CD8 T cells, see below) show a high CD38 cell display (CD38++; > 5000 CD38 molecules/cell) [32]. In fetal cord blood, over 75% of immature T lymphocytes are also CD38++ cells. These populations may thus serve as positive controls when setting the gates for the CD38++ cell populations [29]: in fresh adult blood the standard gate was set between CD38+ neutrophils and CD38++ monocytes, and was further adjusted with cord blood for optimal reproducibility (Fig. 1). As a result, only CD8 T cells with high CD38 cell expression (CD38++, > 5000 CD38 molecules/cell) were scored as ‘positive’ and referred to as ‘CD8+/CD38++'. In the blood of healthy HIV-negative individuals these cells are only present in very low numbers (< 20 cells/mm3 median, 11.0; IQR 7.5, 19.8 cells/mm3;Fig. 1), whereas in cord blood over 75% of T lymphocytes are CD38++ cells.

Other gating strategies, including CD38+/CD8 T cells (1000–5000 CD38 molecules/cell, present mostly on a CD45RA+ cell subset of CD8 T cells) would include normal CD8 T cells in the ‘activated’ gate. This would diminish the powerful discrimination between two inherently different CD8 T cell populations that are the activated CD38++, mostly CD45R0+, CD8 T cells and the normal CD38+, mostly CD45RA+, CD8 T cells.

Back to Top | Article Outline
Statistical methods

Associations between pre-therapy (baseline) variables were assessed using Spearman's rank correlations. Virological and immunological parameters were summarized by medians and IQR. Changes in immunological parameters between time-points were assessed using the Wilcoxon signed-rank test for paired data. Median changes in VL were estimated using the Kaplan–Meier survival analysis technique in order to account for the limit of detection of the assay. The association of baseline CD8+/CD38++ T cells with time to reach VL of less than 50 copes/ml was assessed using a Cox proportional hazards regression model. The associations of: (i) CD8+/CD38++ T cell count during follow-up with the time to first VL of less than 50 copes/ml; and (ii) VL during follow-up with the time to first CD8+/CD38++ T cell count of less than 20 cells/mm3 were assessed using Cox regression models with time-updated covariates, taking the most recent value (usually measured on the same day). Both VL and the CD8+/CD38++ T cell count were logged before inclusion as covariates in Cox regression models. Results from Cox regression models are presented as hazard ratios with 95% confidence intervals (95% CI). All patients who remained under follow-up were included in analyses, irrespective of whether they had stopped or changed antiretroviral therapy. Patients who withdrew from follow-up prematurely were included up to the point of withdrawal.

Back to Top | Article Outline


Correlations at baseline

Of the 148 patients recruited to Quest, full baseline virological and immunological data, including CD8+/CD38++ T cell values, were available for 131 patients recruited from clinics in Europe and Australia. Of these 131 patients (Table 1), 110 were followed-up for at least 28 weeks after HAART initiation; the remaining 21 patients withdrew from the study before week 28. The median pre-therapy CD4 cell count was 450 cells/mm3 (IQR 309, 601; range 113–1295). The median CD8 cell count was 917 cells/mm3 (IQR 581, 1471; range 115–7218) and CD8+/CD38++ T cell count was 461 cells/mm3 (IQR; 216, 974; range, 14–6708). Median VL was 5.45 log copies/ml (IQR 4.8, 5.9; range 2.1–7.6).

When the correlation between virological and immunological parameters was studied at baseline (Table 2) no correlation was found between VL and CD8+/CD38++ T cell counts (r = 0.14;P = 0.11), nor between the CD8+/CD38++ T cell count and the CD4 T cell numbers. However, VL did show a significant inverse correlation with the CD4 T cell count, linking viral replication with CD4 T cell depletion at PHI (r = 0.29;P < 0.001).

Back to Top | Article Outline
Changes in lymphocyte subsets

After the initiation of therapy, CD8+/CD38++ T cell counts declined markedly in peripheral blood (Fig. 2). Within the first 2 weeks of starting therapy, the median level fell from 461 cells/mm3 to 219 cells/mm3 (n = 115) [median change from baseline −261 cells (IQR −668, −44;P < 0.001)], by week 4 (n = 118) the median CD8+/CD38++ cell count was 125 CD8+/CD38++ cells (IQR 78, 308) [median change of −298 cells (IQR −738, −73)]. The median level had fallen to 78 cells/mm3 (n = 105) by week 12 [median change from baseline −420 cells/mm3 (IQR −858, −113)], and to 47 cells/mm3 (IQR 26, 83; n = 92) by week 28 [median change from baseline −436 cells/mm3 (IQR −876, −150)]. The CD8+/CD38++ cell curve showed a two-phase decline: an exponential fall during the first 4 weeks of therapy [median of individual rates of decline 9.9 cells/day (IQR 2.6, 26.8)] followed by a more gradual decline from week 4 to week 28 [median rate of decline 0.40 cells/day (IQR 0.0, 0.97)]. The numbers of patients with a CD8+/CD38++ T cell count within the normal limit (< 20 cells/mm3) at baseline and at weeks 2, 4, 12 and 28 were two out of 131 (1.5%), none, four out of 118 (3.4%), seven out of 105 (6.7%) and 15 out of 92 (16.3%), respectively.

The drop in CD8+/CD38++ T cell counts during the first 4 weeks of treatment coincided with a less marked change in total CD8 T cells by a median of −251 cells (IQR −785, 79) to 660 cells/mm3 (IQR 492, 880; n = 118). However, at week 28 the median CD8 cell counts were relatively unchanged at 695 cells/mm3 (n = 92) [median change from baseline −212 (IQR −746, 102);P < 0.001], indicating that CD8 T cell counts did not continue to decrease between weeks 4 and 28, in contrast to the CD8+/CD38++ T cell counts (Fig. 2). A relatively rapid increase in CD4 T cell counts occurred during treatment in the first 4 weeks of therapy, with a median increase of 121 cells/mm3 (IQR −11, 241;P < 0.001) that reached 211 cells/mm3 (IQR 61, 375) and a median value of 693 cells/mm3 (IQR 521, 868) by week 28.

Back to Top | Article Outline
Correlations between the decline in viral load and other parameters

During the first 4 weeks, VL levels fell by a median of −2.22 (IQR −2.88, −1.77) log copies/ml (adjusted for assay limit < 50 copies/ml) to 3.14 log copies/ml; n = 123. By week 28, VL levels had decreased further to a median of 1.70 copies/ml (n = 93), a median 5.57 log decline from baseline. The continuing marked changes in VL thus mirrored the decline of CD8+/CD38++ cells but not the alterations of total CD8 cell counts (Fig. 2).

Of all the 131 patients who started HAART, 89 patients recorded at least one VL measurement of less than 50 copes/ml during 28 weeks of follow-up. Baseline VL was strongly predictive of time to first VL of less than 50 copes/ml (viral suppression); hazard ratio 1.52 (95% CI 1.18, 1.96, P = 0.001) for every 1 log lower VL. There was also evidence that the baseline CD8+/CD38++ cell count was an independent predictor of time to viral suppression; hazard ratio 1.52 (95% CI 0.96, 2.38), for every 1 log lower baseline CD8+/CD38++ cell count, adjusted for baseline VL, P = 0.072.

During the first 28 weeks after HAART initiation, there was a close relationship between changes in VL and changes in CD8+/CD38++ cell count. When fitting the latest VL assessment as a time-updated covariate in a Cox model of the time to reach a CD8+/CD38++ T cell count of less than 20 cells/mm3 (that occurred in 31 patients), there was a hazard ratio of 2.99 (95% CI 1.35, 6.64) per 1 log lower VL (P = 0.007). Conversely, the latest CD8+/CD38++ T cell count was also strongly associated with the time to a VL of less than 50 copies/ml: a hazard ratio of 3.38 (95% CI 2.01, 5.70) for every 1 log lower CD8+/CD38++ T cell count (P < 0.001).

Changes in CD8+/CD38++ T cell counts were examined in 61 individuals who achieved and maintained a VL below 50 copies/ml, and who had at least two assessments of CD8+/CD38++ T cell counts during the time of virological suppression. Of these 61 patients, 41 (67.2%) experienced a further fall in CD8+/CD38++ T cells, whereas changes in VL were undetectable, with counts remaining below 50 copies/ml. There was a median change in cell numbers of −18 cells/mm3 (IQR −42, 9;P < 0.001) from the first available CD8+/CD38++ T cell count to the last, implying that reductions in CD8+/CD38++ T cells had continued after the plasma VL had become undetectable.

Back to Top | Article Outline


In addition to VL, PHI can be characterized by marked changes in lymphocyte subpopulations and their activation status [7,34]. In the present study, we confirmed previous observations in PHI that have documented marked CD8 lymphocytosis and CD8 activation, determined as an increase in the number of CD8/CD38+ T cells [3,4,7,30]. In other viral infections, CD8 lymphocytosis [35,36], and the upregulation of CD38 expression on CD8 cells are also observed, sometimes even at levels higher than those seen in HIV. With the Epstein–Barr virus (EBV), the average CD8 cell values reached almost 4000 cells/mm3 [34]. Such a response normalizes naturally, with a gradual decline in immune activation once immune control of the acute phase of EBV infection is achieved [37].

Unlike EBV infection, in which latency is established after immune resolution, the passage from the acute to the chronic phase of HIV infection is characterized by the persistence of immune activation. This occurs despite a decrease in the levels of plasma viraemia [2,7,9–11,38]. In contrast to EBV infection, the persistence of high CD8 cell counts and of activated CD8 T cells in HIV infection is thought to reflect the failure of the immune system to suppress viral replication fully [37]. The degree of immune activation further increases with the progression of HIV infection to the later stages of symptomatic HIV disease [10,11,13,17,20,24].

In our cohort of 131 PHI patients, we found high numbers of circulating, activated CD8+/CD38++ T cells at baseline (median of 461 cells/mm3) in agreement with previous observations [22,39,40]. The assay that we employed was standardized to quantitate CD8 immune activation above normal levels by selectively counting activated CD8+/CD38++ T cells that are virtually absent (< 20 cells/mm3) in the blood of healthy HIV-negative individuals (Fig. 1). This elevation of the absolute numbers of CD8+/CD38++ T cell counts in the blood of patients who present at the time of PHI apparently reflects a vigorous immune response to HIV using an assay that effectively discriminates between activated (CD38++) and normal (CD38− and CD38+) CD8 T cell populations.

Perhaps the most significant observations of the study were that viral replication was effectively inhibited with a potent HAART combination during PHI, and that this decrease in VL was mirrored by a profound and rapid decline in the CD8+/CD38++ T cells. The number of cells decreased to approximately one sixth of the pre-therapy value by week 12 of HAART intervention. In the majority of patients, the VL was no longer detectable (< 50 copies/ml) by week 28, and the CD8+/CD38++ T cell values were fully normalized in 16% of our cohort, and showed only moderate elevation above the levels in healthy HIV-negative individuals. Indeed, we observed a continued decline in median CD8+/CD38++ T cell counts after VL levels had declined below 50 copies/ml. Consequently, a longer follow-up of this cohort is warranted to assess whether a sustained period of antiviral therapy can fully reverse T cell activation, as defined by CD8+/CD38++ cell counts, in patients who respond to treatment.

It is relevant to the lack of correlation between VL and CD8+/CD38++ cell counts at baseline to consider the absence of a steady state of the VL at this very early stage of infection. Changes in VL appeared to precede CD38++ cell alterations. In approximately a fifth of our patients, the CD8+/CD38++ cell counts were still on the increase and peaked after treatment initiation, whereas VL was invariably highest at presentation. At weeks 2 and 4 after treatment initiation, the correlation between VL and CD8+/CD38++ cell counts appeared to strengthen, increasing from r = 0.37 (P < 0.001, n = 111) to r = 0.43 (P < 0.001, n = 117).

Unfortunately, the protocol for the present study did not include the concomitant investigation of an untreated PHI control group. However, in a small historical control cohort of untreated patients (n = 9) at weeks 20 and 28, estimated time-points after seroconversion, the average level of CD8+/CD38++ cells remained 222 and 181, respectively, and we were not able to find a normalization of CD8+/CD38++ cell numbers. in any of these patients. Furthermore, in six QUEST patients who discontinued therapy after achieving viral suppression, we observed a simultaneous increase in CD8+/CD38++ cell counts and VL after treatment cessation. These data suggest that, in the absence of therapy, increased levels of CD8+/CD38++ cells indeed persist during the passage from acute to chronic infection.

Back to Top | Article Outline


The marked rate at which CD8+/CD38++ T cells disappear from the peripheral blood after viral inhibition, with a halving in numbers within the first 2 weeks of treatment, has implications for understanding the role of CD8+/CD38++ T cells. During the first 2 weeks, the rapid decline in VL and CD8+/CD38++ T cell counts could not be wholly attributed to therapy. Such cells undergo rapid apoptosis or exit from the peripheral blood [41,42]. The parallel loss of total CD8 and CD8+/CD38++ T cell numbers during this early phase would also be consistent with CD8+/CD38++ T cell death or exit from the bloodstream to tissues. This agrees with our findings in the historical control cohort, who showed a similar decline to week 4. However, by week 4, the decrease in CD8+/CD38++ T cell counts was already more profound in the treated as opposed to the untreated patients. Furthermore, at 28 weeks, the decline in CD8+/CD38++ T cells was far more pronounced than that of the total CD8 T cells, implying that, in the absence of further viral stimulation, a significant number of CD8+/CD38++ T cells must have differentiated or downregulated their high CD38++ cell phenotype [43].

Although VL and CD8+/CD38++ T cell levels were not closely related at baseline, an intimate relationship developed between these parameters during therapy. Once treated, those individuals with the lowest VL values at follow-up were more likely to reach a CD8+/CD38++ T cell count of less than 20 cells/mm3. CD8+/CD38++ T cell counts may represent a sensitive measure of residual viral replication during therapy, and may provide a predictive parameter for response to therapy, defined as VL falling below 50 copies/ml.

Further studies are needed to assess the sensitivity of CD8+/CD38++ cell as a marker of low-level viral replication. As the CD8+/CD38++ cell assay is simple but not HIV specific, it may be employed as an early warning signal in three related areas. First, a study would benefit from a coordinated use of this simple flow cytometric assay, and particularly sensitive virological methods of HIV detection in the blood down to a level of 3 copies/ml [40]. Second, this cellular test may also reflect the existence of viral reservoirs in other body compartments, such as the lymph nodes, at a time when VL in the blood remains undetectable as suggested by others [44]. Finally, the early signs of immune activation might provide the clinician with a warning of patient non-compliance or viral rebound after the cessation of HAART or during its intermittent use.

Back to Top | Article Outline


The QUEST study group wishes to thank all the QUEST scientists for their advice and work, and physicians and nurses for patient referral and clinical care, and the patients for their participation, cooperation and dedication to this study.

We would also like to thank the local study monitors in Australia (M Haberl, J Young), Belgium (D Luyts), Canada (S Pratt), Denmark (R Balschmidt), France (JM Vauthier), Germany (M Sikora), Italy (C Gussetti, CM Anghileri, V Piva), Sweden (G Larrson), Switzerland (I Schauwecker, E Gremlich, C Python) and the UK (P Humphreys). Special mention also goes to the lead investigators in Australia (D Baker, M Bloch, D Smith, P Cunningham, D Cooper, R Finlayson), Belgium (N Clumeck), Canada (J Montaner, C Tsoukas), Denmark (L Mathiesen), France (PM Girard, J Modai, F Raffi, Saitmt), Germany (S Staszewski, H Stellbrink), Italy (A Lazzarin, G Tambussi), Sweden (H Gaines), Switzerland (M Battergay, K Wolfe, L Perin, P Vernazza, R Weber) and the UK (MJ Fisher, B Gazzard, D Hawkins, M Tyrer, M Youle, M Kahan and M Johnson), as well as the Quest Team at GlaxoSmithKline, UK (V Mallet, S Turkish, O Fortes, H Maseruka and H McDade) and Roche Molecular Systems (B Dale and A Capt).

Back to Top | Article Outline


1. Giorgi JV, Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS Cohort Study. Clin Immunol Immunopathol 1989, 52: 10–18.
2. Janossy G, Autran B, Miedema F. Immunodeficiency in HIV infection and AIDS. Basel; New York: Karger; 1992.
3. Prince HE, Jensen ER. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr 1991, 4: 1227–1232.
4. Yagi MJ, Chu FN, Jiang JD. et al. Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection. Clin Immunol Immunopathol 1992, 63: 126–134.
5. Zaunders JJ, Cunningham PH, Kelleher AD. et al. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999, 180: 320–329.
6. Carcelain G, Blanc C, Leibowitch J. et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS 1999, 13: 1077–1081.
7. Cossarizza A, Ortolani C, Mussini C. et al. Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome. J Infect Dis 1995, 172: 105–112.
8. Giorgi JV, Ho HN, Hirji K. et al. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38− CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis 1994, 170: 775–781.
9. Ho HN, Hultin LE, Mitsuyasu RT. et al. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993, 150: 3070–3079.
10. Kestens L, Vanham G, Gigase P. et al. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS 1992, 6: 793–797.
11. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992, 90: 376–382.
12. Vanham G, Kestens L, Penne G. et al. Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection. J Clin Immunol 1991, 11: 345–356.
13. Bofill M, Mocroft A, Lipman M. et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996, 10: 827–834.
14. Giorgi JV, Hultin LE, McKeating JA. et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179: 859–870.
15. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993, 6: 904–912.
16. Liu Z, Hultin LE, Cumberland WG. et al. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry 1996, 26: 1–7.
17. Mocroft A, Bofill M, Lipman M. et al. CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14: 158–162.
18. Perfetto SP, Malone JD, Hawkes C. et al. CD38 expression on cryopreserved CD8+ T cells predicts HIV disease progression. Cytometry 1998, 33: 133–137.
19. Vigano A, Saresella M, Rusconi S, Ferrante P, Clerici M. Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy. Lancet 1998, 352: 1905–1906.
20. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18: 332–340.
21. Bisset LR, Cone RW, Huber W. et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS 1998, 12: 2115–2123.
22. Bouscarat F, Levacher M, Landman R. et al. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998, 12: 1267–73.
23. Evans TG, Bonnez W, Soucier HR, Fitzgerald T, Gibbons DC, Reichman RC. Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Antiviral Res 1998, 39: 163–73.
24. Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998, 12: 1833–1844.
25. Gray CM, Schapiro JM, Winters MA, Merigan TC. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998, 14: 561–569.
26. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173: 321–329.
27. Silvestri G, Munoz C, Butini L, Bagnarelli P, Montroni M. Changes in CD8 cell subpopulations induced by antiretroviral therapy in human immunodeficiency virus infected patients. Viral Immunol 1997, 10: 207–212.
28. Hultin LE, Matud JL, Giorgi JV. Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator. Cytometry 1998, 33: 123–132.
29. Gratama JW, D'Hautcourt JL, Mandy F. et al. Flow cytometric quantitation of immunofluorescence intensity: problems and perspectives. European Working Group on Clinical Cell Analysis. Cytometry 1998, 33: 166–178.
30. Zaunders J, Carr A, McNally L, Penny R, Cooper DA. Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes. AIDS 1995, 9: 561–566.
31. Goh L, Perrin L, Hoen B. et al. The Quest trial: evaluation of the potential for durable viral suppression following quadruple HAART with or without HIV vaccination in primary HIV infection. HIV Clin Trials 2001, 2: 434–444.
32. Mercolino TJ, Connelly MC, Meyer EJ. et al. Immunologic differentiation of absolute lymphocyte count with an integrated flow cytometric system: a new concept for absolute T cell subset determinations. Cytometry 1995, 22: 48–59.
33. Janossy G, Bikoue A, Tilling RE, Reilly JT, Granger V, Barnett D. Stabilized cellular immunofluorescent analysis (SCIFA): A new concept for quantitative flow cytometry in routine immunohaematology. Cytometry 1998, 101 (Suppl. 1) : 330.330.
34. Kinloch-De Loes S, Hirschel BJ, Hoen B. et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995, 333: 408–413.
35. Crawford DH, Brickell P, Tidman N, McConnell I, Hoffbrand AV, Janossy G. Increased numbers of cells with suppressor T cell phenotype in the peripheral blood of patients with infectious mononucleosis. Clin Exp Immunol 1981, 43: 291–297.
36. Reinherz EL, Kung PC, Goldstein G, Schlossman SF. A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH2. J Immunol 1980, 124: 1301–1307.
37. Lynne JE, Schmid I, Matud JL. et al. Major expansions of select CD8+ subsets in acute Epstein–Barr virus infection: comparison with chronic HIV disease. J Infect Dis 1998, 177: 1083–1087.
38. Hulstaert F, Hannet I, Deneys V. et al. Age-related changes in human blood lymphocyte subpopulations. II Varying kinetics of percentage and absolute count measurements. Clin Immunol Immunopathol 1994, 70: 152–158.
39. Burgisser P, Hammann C, Kaufmann D, Battegay M, Rutschmann OT. Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study. Clin Exp Immunol 1999, 115: 458–463.
40. Orendi JM, Bloem AC, Borleffs JC. et al. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 1998, 178: 1279–1287.
41. Mahalingam M, Pozniak A, McManus TJ, Vergani D, Peakman M. Cell cycling in HIV infection: analysis of in vivo activated lymphocytes. Clin Exp Immunol 1995, 102: 481–486.
42. Gougeon ML, Lecoeur H, Dulioust A. et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996, 156: 3509–3520.
43. Garcia F, Vidal C, Plana M. et al. Residual low level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis 2000, 30: 392–394.

Cited By:

This article has been cited 5 time(s).

Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence?
Smith, DE; Walker, BD; Cooper, DA; Rosenberg, ES; Kaldor, JM
AIDS, 18(5): 709-718.

PDF (137)
JAIDS Journal of Acquired Immune Deficiency Syndromes
Initiation of Antiretroviral Therapy at CD4 Cell Counts ≥350 Cells/mm3 Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal Insufficiency
Lichtenstein, KA; Armon, C; Buchacz, K; Chmiel, JS; Moorman, AC; Wood, KC; Holmberg, SD; Brooks, JT; the HIV Outpatient Study (HOPS) Investigators,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 47(1): 27-35.
PDF (466) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
CD4+ T-Cell Immunodeficiency Is More Dependent on Immune Activation Than Viral Load in HIV-Infected Children on Highly Active Antiretroviral Therapy
Resino, S; Seoane, E; Gutiérrez, MG; León, JA; Muñoz-Fernández, MÁ
JAIDS Journal of Acquired Immune Deficiency Syndromes, 42(3): 269-276.
PDF (717) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
HIV-Producing T Cells in Cerebrospinal Fluid
Neuenburg, JK; Sinclair, E; Nilsson, A; Kreis, C; Bacchetti, P; Price, RW; Grant, RM
JAIDS Journal of Acquired Immune Deficiency Syndromes, 37(2): 1237-1244.

PDF (182)
JAIDS Journal of Acquired Immune Deficiency Syndromes
Increased Proportions of Activated and Proliferating Memory CD8+ T Lymphocytes in Both Blood and Lung are Associated with Blood HIV Viral Load
Barry, SM; Johnson, MA; Janossy, G
JAIDS Journal of Acquired Immune Deficiency Syndromes, 34(4): 351-357.

PDF (376)
Back to Top | Article Outline

Antiretroviral therapy CD38; HIV; lymphocyte activation; primary HIV infection

© 2002 Lippincott Williams & Wilkins, Inc.